Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774665 · ClinicalTrials.gov registry record · Phase 2
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
A Phase 2 study of Overweight and Inflammation, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT05774665 is a Phase 2 study of Overweight and Inflammation that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05774665, a Phase 2 study of Overweight and Inflammation, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard antidepressant treatment. The main questions it seeks to answer are: 1. Do omega-3 fatty acids added to ineffective antidepressant treatment increase production of compounds that reduce inflammation? 2. Is the increase in these anti-inflammatory compounds associated with a stronger antidepressant effect? Participants taking antidepressants that have not worked completely will be assigned at random for a 12-week period to one of the following: 1. an omega-3 preparation 2. an inactive placebo During the course of the study, blood tests will be obtained for compounds associated with inflammation, and questionnaires to measure clinical improvement in depressive symptoms will be administered.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Omega 3
Study Locations (3)
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Depression Clinical and Research Program at Massachusetts General Hospital - Boston
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05774665
The ClinicalTrials.gov registry entry for NCT05774665 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05774665 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Massachusetts, Utah.
Frequently Asked Questions
What is clinical trial NCT05774665 about?
NCT05774665 is a clinical study titled "Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression". The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard antidepressant treatment. The main questions it seeks to answer are: 1. Do omeg...
What is the current status of trial NCT05774665?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-01-30. Estimated completion is 2026-03-31.
What conditions does trial NCT05774665 study?
This clinical trial studies the following conditions: Overweight, Inflammation, Treatment-Resistant Depression.
What interventions are being tested in trial NCT05774665?
The interventions under investigation include: Placebo (OTHER), Omega 3 (DRUG).
Who is sponsoring clinical trial NCT05774665?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774665 being conducted?
This trial has 3 study locations across Georgia, Massachusetts, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
RECRUITING · Phase 2
-
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
RECRUITING · Phase 2
-
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
RECRUITING · Phase 2
-
Semaglutide for Post-Smoking Cessation Weight Management
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.